Study S002332

A Phase 1, Randomised, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of XW003 Injection in Healthy Adult Participants

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT04389775
Acronym: XW003
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 64
Start: 2020-03-29
Primary completion: 2021-09-29
Lead sponsor: Sciwind Biosciences APAC CO Pty. Ltd.
Conditions: Type 2 Diabetes Mellitus; Obesity; Nonalcoholic Steatohepatitis
Interventions: DRUG:Cohort A; DRUG:Placebo A; DRUG:Cohort B; DRUG:Placebo B
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: REGISTRY:ACTRN12620000344998

Registered primary outcomes

Number of treatment emergent adverse events (TEAEs) [From administration of XW003 on Day 1 to the last follow-up visit]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0009494	Discovery of ecnoglutide - A novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog. Guo W, Molecular metabolism	2023	Randomized trial	PMID 37364710 DOI	cites ClinicalTrials.gov:NCT04389775; registry reference DERIVED:37364710